Project

Biotechnology netherlands

Leiden Analytics

Technologies to help us understand the biology underlying drug response are in high demand, as many patients do not respond to treatments. Identifying potential responders is particularly important in modern cancer care, where therapies are potentially very effective yet extremely expensive. There is need of more in-depth understanding of which rare cell populations, (e.g. inside of a tumor) can influence the effectiveness of a drug treatment.

Single-cell analysis is a breakthrough technology to understand the biology of drug response, as it enables the detection of cell-to-cell variation thereby providing insights that are inaccessible when analyzing cells in bulk. We need biomarkers to detect the presence and the function of such cell populations.

Standard methods cannot easily distinguish the signal of a small, informative cell population from the bulk of the cells being analyzed. Powerful techniques, such as mass spectrometry-based proteomics, are lagging far behind genetics because of technical challenges. Metabolomics could be a solution, if ported to single cell level, because metabolic biomarkers are the most informative of cellular functions. Metabolomics consists of measuring a wide range of small endogenous molecules (typically in blood) and getting an accurate snapshot of someone’s actual physiology and health state.

Project Leiden Analytics will deliver a high-throughput, quantitative, single cell metabolomics platform built on LU-patented technology. In this Level 1 project, the platform will be first tested in an immuno-oncology application, because single cells analysis of circulating immune cells is considered one of the most effective ways to capture cells greatly affecting therapy effectiveness. The ambitious objective of this project is to detect metabolites predictive of which patients will respond to immunotherapy.

Project team

Thomas Hankemeier

Project Number

BIOB24073

Year granted

2024

Status

Ongoing

Applicant

Leiden University

Funding

€ 200.000

Sector/Industry

SDG's

Thematic Cluster

TC4: Diagnostics and Services

Level

Level 1
Molecuul

2024

Year granted

Leiden University

Applicant

€ 200.000

Project funded
Project story

Plant Beams: breaking through the plant barrier

The question that started Plant Beams For over ten years, David Fernández Rivas has worked on a technology that uses

Plant Beams: breaking through the plant barrier
Project story

SideroFORCE: Tricking bacteria to heal infection

We interviewed Wim Velema, projectleader of Biotech Booster project SideroFORCE, which joined our program in 2025. At sixteen, Wim liked

SideroFORCE: Tricking bacteria to heal infection
IBB

Behind the Bootcamp: Meet the IBB26 Coaches

Building an industrial biotech venture takes more than a great scientific idea. It requires the ability to challenge assumptions, make

Behind the Bootcamp: Meet the IBB26 Coaches
Project story

From Luggage Tags to Better Food

From fragmented DNA to better food on our plates. We interviewed Biotech Booster project Haplotagging to learn more about their

From Luggage Tags to Better Food
Impact developer portrait

The Innovation Journey at the Universities of Applied Sciences

Impact Developers help researchers turn their ideas into innovations that impact society. They connect researchers with companies and other partners

The Innovation Journey at the Universities of Applied Sciences
Alumni Column

Alumni column: Patrick Dekker from iProtics

On both sides of the table. Some people know Biotech Booster from the outside. Others experience it from the inside,

Alumni column: Patrick Dekker from iProtics
Citaat

Biotech Booster helps us through funding and by providing us with a network to validate where we can make the best impact with our new analysis device.

Biotechnology netherlands

Carlos de Lannoy

Constellate

Citaat

What we look forward to most is leveraging the extraordinary network of Biotech Booster that we need to get foot in the market, get know-how, and understanding the competitive field which is necessary for setting up successful operations.

Biotechnology netherlands

Pim Schaasberg & Martin Pabst

ProteoT

Moleculen

Newsletter

Receive monthly updates about our community!

Subscribe to our newsletter